Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
87 results about "Benign hemangiomas" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Hemangioma is a benign tumor formed by a collection of excess blood vessels. A hemangioma may be visible through the skin as a birthmark, known colloquially as a strawberry mark. Most hemangiomas that occur at birth disappear after a few months or years.
An anti-tumor compound and its preparation method, application, and pharmaceutical compositions
InactiveCN102924507AHighly directional (targeted) selectionOrganic active ingredientsGroup 5/15 element organic compoundsDiseaseEster prodrug
The present invention discloses an anti-tumor compound and its preparation method,application, and pharmaceutical compositions. The anti-tumor compound is a 4 - nitro-substituted benzyl group ifosfamide ester prodrug thereof, or pharmaceuticallysalt, or solvate thereof of the structure of formula I. The structure of formula I. The present invention has the following advantage of being used for the treatment or prevention of mammalian tumor-related diseases, such as leukemia, hemangioma, glioma, Kaposi's sarcoma, ovarian cancer, breast cancer, lung cancer, pancreatic cancer, lymphoma, prostate, colon and skin tumors and their complications.
Owner:ANHUI SIWEI PHARMA
Retina hemangioma image segmentation method based on GAN (Generative Adversarial Network)
PendingCN108537801AGuaranteed resolutionReduce data volumeImage enhancementImage analysisDiscriminatorPattern recognition
The invention discloses a retina hemangioma image segmentation method based on a GAN (Generative Adversarial Network), and the method comprises the steps: constructing a GAN structure, wherein the GANstructure comprises a generator and a discriminator, the generator comprises a plurality of downsampling layers and an equal number of upsampling layers, and the discriminator comprises a plurality of downsampling layers; taking a hemangioma artificial segmented image and an original fundus retina image as training data, performing iterative training of the GAN, and obtaining an optimal generator; performing hemangioma image segmentation of a to-be-segmented fundus retina image based on the optimal generator. Compared with a conventional retina hemangioma image segmentation method based on animage processing algorithm, the method can achieve the more accurate and clear segmentation of the image, reduces a false positive segmentation result, and is more precise in image segmentation details.
Owner:SHANDONG UNIV
Propranolol hydrochloride gel for treating infant superficial hemangioma
ActiveCN102871956AEasy to makeLow costOrganic active ingredientsAerosol deliveryDecreasing heart rateGranular Leukocytes
The invention belongs to the technical field of medicines, and provides a propranolol hydrochloride (PPL.HCL) gel which can be externally used for treating infant superficial hemangioma. The propranolol hydrochloride gel is mainly prepared from propranolol hydrochloride, gel matrix, a percutaneous penetration enhancer, a preservative, a humectant and the like. By using the propranolol hydrochloride gel, adverse reactions such as decreased heart rate, cyanosis, airway hyperresponsiveness, shortage of granular leukocytes, diarrhoea, sleep change and blood sugar reduction caused by orally taking propranolol by hemangioma patients can be reduced and even avoided, and the problems that oral dosage is not easy to control, infants inconveniently take medicines and the like are solved.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV
Application of tetracyclic triterpenoids compound in preparing anti-angiogenic drugs
InactiveCN101647801AEnhanced inhibitory effectOrganic active ingredientsSenses disorderDiseaseAdditive ingredient
The invention provides the application of tetracyclic triterpenoids compound cucurbitacins E in preparing anti-angiogenic drugs. The cucurbitacins E can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi' s sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget' s disease angiogenesis. The invention also provides the application of a compound containing effective dose of cucurbitacins E and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.
Owner:EAST CHINA NORMAL UNIVERSITY
Matrix metallo-proteinase inhibitor polypeptide and application thereof
ActiveCN103145855ASuppress acute inflammationPeptide/protein ingredientsAntipyreticKidneyCervix uterus
The invention relates to the field of medicines, and in particular relates to an inhibitor of angiogenesis capable of inhibiting matrix metallo-proteinase and migration of vascular endothelial cells. The inhibitor can be used for preventing and treating solid tumor and rheumatoid arthritis. The polypeptide specifically means polypeptide I, polypeptide II, polypeptide III and polypeptide IV (with reference to SeqNO.1, SeqNO.2, SeqNO.3 and SeqNO.4). The polypeptide can be used for treating solid tumor and rheumatoid arthritis. The four inhibitors of angiogenesis can be applied to preparing medicines for treating tumor. The polypeptide is characterized in that tumor is originated from essential or subsequent cancers, melanoma, hemangioma and sarcoma of heat and neck, brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gall bladder, colon or rectum, ovary, cervix uterus, uterus, prostate, bladder and testis.
Owner:NANJING ANJI BIOLOGICAL TECH CO LTD
Treatment of cutaneous hemangioma
InactiveUS20120058056A1Small sizeEffective treatmentBiocidePeptide/protein ingredientsBeta blockerHemangioma
This invention concerns a method of treating hemangiomas with a beta blocker by applying the beta blocker onto the hemangiomas directly. The invention also concerns a combination therapy by using a beta blocker along with a corticosteroid or an alpha adrenergic receptor agonist for the treatment of hemangiomas.
Owner:RUTGERS THE STATE UNIV
Application of osthole in preparing anti-angiogenic drugs
The invention provides an application of osthole in preparing anti-angiogenic drugs. The osthole can inhibit tumor angiogenesis, arthritis pathological tissue vessel angiogenesis, neovascular eye disease, hemangioma pathological tissue angiogenesis, psoriasis pathological tissue vessel angiogenesis, solid tumor pathological tissue angiogenesis, hemangioma, Kaposi's sarcoma pathological tissue angiogenesis, leukocythemia, lymphadenoma, myeloma blood cancer and Paget's disease angiogenesis. The invention also provides the application of a compound containing effective dose of osthole and pharmacy acceptable ingredients in preparing the anti-angiogenic drugs.
Owner:EAST CHINA NORMAL UNIV
Sodium alginate microballoon vein suppository containing hemangioma-resisting medicant, preparation method and application thereof
InactiveCN101536987AGood treatment effectReduce systemic side effectsSurgeryPharmaceutical product form changeEmbolization AgentBiocompatibility Testing
The invention discloses a sodium alginate microballoon vein suppository containing hemangioma-resisting medicant, a preparation method and an application thereof. The sodium alginate microballoon vein suppository comprises carrier sodium alginate and hemangioma-resisting medicant; the sodium alginate covers the hemangioma-resisting medicant; the weight ratio of the sodium alginate to the hemangioma-resisting medicant is 5:1-60:1; and the hemangioma-resisting medicant is pingyangmycin, sodium morrhuate, carbamide or bleocin. The raw materials used in the invention have favorable mechanical strength, biocompatibility, biological degradability and stability, have no organic solvent, and are basically harmless to functions of hemopoietic system and immune system, thereby suppository can be industrially produced.
Owner:BEIJING SHENGYIYAO SCI & TECH DEV
Injection for curing angiomatous
InactiveCN101284127AOrganic active ingredientsPeptide/protein ingredientsDexamethasoneCurative effect
The invention relates to an injection for treating hemangioma, which is prepared from interferon, dexamethasone, adrenaline, lidocaine and water for injection. The preparation method comprises dissolving pingyangmycin (8 mg) into 2% lidocaine injection to reach volume of 3 ml; dissolving interferon (3,000,000 unit) into water for injection to reach volume of 3 ml; mixing diluted pingyangmycin (2 ml), diluted interferon (1 ml), dexamethasone (1 ml), adrenaline (0.5 ml), 2% lidocaine (2.5 ml) and water for injection (3 ml); and making into injection. The injection has good curative effect on hemangioma, convenient application, and no restriction to medical treatment condition.
Owner:广水市第一人民医院
Isolation and growth of stem cells from hemangiomas
InactiveUS20080299077A1Peptide/protein ingredientsMicrobiological testing/measurementProgenitorAngiogenic inhibitors
The present invention describes stem cells and progenitor cells derived from hemangiomas, including testing of angiogenic inhibitors using these cells. The invention as described is useful in providing a process to culture and propagate hemangioma stem cells and generate xenograft models to develop treatments for infantile hemangiomas and other types of vascular lesions.
Owner:NEVADA CANCER INST
Pingyangmycin polyethylene glycol (PEG)-polycaprolactone (PCL)-polyethylene glycol (PEG) temperature-sensitive slow-release gel, as well as preparation method and application of same
ActiveCN102836418AExtended half-lifeExtension of timeAerosol deliveryOintment deliverySide effectHalf-life
The invention discloses a pingyangmycin polyethylene glycol (PEG)-polycaprolactone (PCL)-polyethylene glycol (PEG) temperature-sensitive slow-release gel, as well as a preparation method and the application of the gel. The Pingyangmycin PEG-PCL-PEG temperature-sensitive slow-release gel mainly consists of two parts comprising PEG (polyethylene glycol)-PCL (polycaprolactone)-PEG (polyethylene glycol) co-polymer and Pingyangmycin, is liquid at room temperature, and is solid gel under the in vivo 37 DEG C condition; the gel system has significant slow-release effect, thereby having functions in prolonging the half-life period and the acting time of the Pingyangmycin, reducing drug concentration in plasma, and reducing systemic toxic and side effects. The gel can be formed in situ after the medicine is injected in a high-flow-speed vessel, and then location embolism is realized, and so as to realize the, and muscularization and closing of muscle is caused, so that the sclerotherapy and the interventional therapy are combined effectively, the gel has excellent biocompatibility and degradability, is beneficial for treating hemangiomas, vascular malformations and cancers, particularly, a new selection is provided to the treatment of the vein malformation and partial malformation of cancers.
Owner:WUHAN UNIV
External medicament for treating infant hemangioma and preparation method thereof
InactiveCN102579412ALower blood pressureOrganic active ingredientsAerosol deliveryGlycerolWater soluble
The invention discloses an external medicament for treating infant hemangioma and a preparation method thereof, which belong to the technical field of medicine. The external medicament comprises the following components: propranolol, stearic acid, glycerin monostearate, white Vaseline, azone, oleic acid, Tween-80, glycerol, deionized water and ethylparaben. The method comprises the following steps of: accurately weighing a certain amount of greasy component and a certain amount of water-soluble component respectively, and heating and preserving heat respectively at 75+ / -2 DEG C; and slowly adding the greasy component into the water-soluble component, and continuously stirring along the same direction till the mixture is fully emulsified and is condensed into paste. The external medicament is safe and reliable. As proved by clinical experiments, after the external medicament is uniformly smeared onto the surface of a tumor body, the tumor body is faded remarkably 2-3 months later, 59 percent of infant patients can be cured 5-7 months later, 33 percent of tumor bodies are faded remarkably, and the total yield is 92 percent.
Owner:SHANDONG PROVINCIAL HOSPITAL
Decapeptide inhibiting angiogenesis and use thereof
InactiveCN101597324AEnhanced inhibitory effectSenses disorderPeptide/protein ingredientsDiseaseVascular endothelium
The invention relates to a decapeptide inhibiting angiogenesis and use thereof, belonging to the technical field of biological medicine. The decapeptide inhibiting angiogenesis provided by the invention is deprived from human Homo sapien with an amino acid sequence of YNWNSFGLRF and the molecular weight of 1303.4, and is named as Kp-10. The invention further provides use of the decapeptide inhibiting angiogenesis for preparing medicines for inhibition of angiogenesis, in particular relevant use of Kp-10 for preparing medicines for inhibition of angiogenesis dependent diseases such as cancer, rheumatoid arthritis, psoriasis, diabetes syndrome, and hemangioma. A series of experimental results in VEGF (Vascular Endothelial Growth Factor) induction shows that Kp-10 has obvious inhibition function in the proliferation experiment of human umbilical vein endothelial cells (HUVEC), transfer experiment, micro-tube forming experiment, angiogenesis experiment of chick embryo allantois and mouse cornea experiment, and the decapetide can be used for preparing medicines for inhibiting angiogenesis.
Owner:EAST CHINA NORMAL UNIV
Chinese medicine composition for treating cutaneous hemangioma
InactiveCN102091290ANo side effectsLow priceUnknown materialsCardiovascular disorderMedicinal herbsSide effect
The invention provides a Chinese medicine composition capable of effectively treating cutaneous hemangioma, belonging to the field of Chinese medicines. the Chinese medicine composition for treating cutaneous hemangioma is characterized by being prepared from the Chinese medicinal herbs in parts by weight: 10 parts of astragalus mongholicus, 10 parts of rhizoma smilacis glabrae, 8 parts of dangshen, 12 parts of unprocessed rehmannia root, 15 parts of polygonum multiflorum, 20 parts of radices lithospermi, 12 parts of moutan bark, 15 parts of white paeony root, 8 parts of rhizoma corydalis, 5 parts of golden cypress, 5 parts of rhizoma anemarrhenae, 15 parts of Chinese thorowax root, 12 parts of radix curcumae, 12 parts of rhizoma sparganii, 10 parts of curcuma zedoary, 15 parts of calculus bovis and 20 parts of safflower carthamus. The Chinese medicine composition is prepared from the natural Chinese medicinal herbs as raw materials, is used for treating the cutaneous hemangioma by using combined action of all Chinese medicinal herbs, has no toxic and side effects to a human body, and has the advantages of low cost, capability of treating both principal and secondary aspect of the cutaneous hemangioma, and accurate treatment effect. Proved by 100 patients in clinical, the Chinese medicine composition for treating the cutaneous hemangioma has a cure rate of 96.0 percent, wherein 96 patients are cured and 4 patients get better.
Owner:冯业进
Propranolol hydrochloride gel for treating infant superficial hemangioma
ActiveCN102871956BGood percutaneous penetrationAchieving local therapeutic concentrationsOrganic active ingredientsAerosol deliveryDecreasing heart rateBlood sugar
The invention belongs to the technical field of medicines, and provides a propranolol hydrochloride (PPL.HCL) gel which can be externally used for treating infant superficial hemangioma. The propranolol hydrochloride gel is mainly prepared from propranolol hydrochloride, gel matrix, a percutaneous penetration enhancer, a preservative, a humectant and the like. By using the propranolol hydrochloride gel, adverse reactions such as decreased heart rate, cyanosis, airway hyperresponsiveness, shortage of granular leukocytes, diarrhoea, sleep change and blood sugar reduction caused by orally taking propranolol by hemangioma patients can be reduced and even avoided, and the problems that oral dosage is not easy to control, infants inconveniently take medicines and the like are solved.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV
Vanadium compounds as anti-angiogenic agents
Owner:PARKER HUGHES INST
Timolol external preparation for treating hemangioma
InactiveCN105998178ABroaden applicationGood curative effectOrganic active ingredientsAerosol deliveryMedicineAdditive ingredient
The invention discloses a timolol external preparation for treating hemangioma. The prepared external preparation is ointment or gel prepared in the mode that two active ingredients including timolol and oleum menthae are added into a gel matrix or an ointment matrix, wherein the content of the timolol, by mass, accounts for 0.25-1% of the ointment or the gel, and the content of the oleum menthae, by mass, accounts for 1% of the ointment or the gel. The preparation method comprises the steps that timolol is prepared into a timolol saline solution in a salifying mode, the active ingredient oleum menthae is added into the timolol saline solution, the obtained solution is dispersed into the gel matrix according to the weight ratio of (1:1)-(1:10) to be subjected to swelling, and the gel is obtained; or the obtained solution is dispersed into the ointment matrix according to the weight ratio of (2.5:1)-(3:1), and the ointment is obtained. The preparation process is simple, easy to practice and applicable to requirements of industrial mass production. Pharmacodynamics results prove that the effective ingredients timolol and oleum menthae in the external preparation have the synergism for treating hemangioma and good tolerance, and no adverse reaction occurs.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY
Early warning system for ruptured artery hemangioma and early warning method thereof
ActiveCN106859620AAvoid damageExtensibilityCatheterDiagnostic recording/measuringBenign hemangiomasBlood vessel
The invention discloses an early warning system for ruptured artery hemangioma and an early warning method thereof. According to the invention, an ultrathin flexible sensor, ultrathin flexible temperature sensors and an ultrathin flexible strain sensor are implanted into the body through minimally invasive surgery; the strain sensor is wound and attached to the position of the hemangioma; the temperature sensors are wound and attached to the equidistant positions upstream and downstream the hemangioma; the early warning system has ultrahigh biological compatibility and will not cause internal rejection reaction; the sensors are directly and tightly attached to the measured positions and can be used for timely and accurately measuring the measured parameters; the ultrathin flexible characteristics of the sensors will not cause new focus by resulting in external damage to blood vessels and tissues; the signal is transmitted to a mobile terminal in the manner of near field communication; a microprocessor in the mobile terminal has an alarming function; when a deforming value or local blood pressure value of the hemangioma exceeds a threshold value, the microprocessor can alarm, so that the early warning system can conveniently monitor and measure early warning for a long time.
Owner:TSINGHUA UNIV
Curcumin and curcuminoid inhibition of angiogenesis
InactiveUS20090018209A1Inhibit angiogenesisImprove the level ofBiocideDigestive systemRecessive dystrophic epidermolysis bullosaSturge–Weber syndrome
Methods for treating diseases or disorders of the skin which are characterized by angiogenesis have been developed using curcumin and curcumin analogs. Based on the results obtained with curcumin, it has been determined that other angiogenesis inhibitors can also be used to treat these skin disorders. It has further been discovered that curcumin acts to inhibit angiogenesis in part by inhibition of basic fibroblast growth factor (bFGF), and thereby provides a means for treating other disorders characterized by elevated levels of bFGF, such as bladder cancer, using curcumin and other analogues which also inhibit bFGF. Representative skin disorders to be treated include the malignant diseases angiosarcoma, hemangioendothelioma, basal cell carcinoma, squamous cell carcinoma, malignant melanoma and Karposi's sarcoma, and the non-malignant diseases or conditions including psoriasis, lymphangiogenesis, hemangioma of childhood, Sturge-Weber syndrome, verruca vulgaris, neurofibromatosis, tuberous sclerosis, pyogenic granulomas, recessive dystrophic epidermolysis bullosa, venous ulcers, acne, rosacea, eczema, molluscum contagious, seborrheic keratosis, and actinic keratosis.
Owner:EMORY UNIVERSITY
A long-acting timolol transdermal preparation and its application in hemangioma
ActiveCN104274390BImproves the efficiency of drug absorptionGood treatment effectOrganic active ingredientsAerosol deliveryTherapeutic effectHemangioma
The invention relates to a timolol long-acting transdermal preparation, the preparation process of which comprises: first preparing timolol into timolol nano-medicine or timolol micropowder, and then preparing timolol nano-medicine Or timolol micropowder is prepared into timolol hydrogel transdermal preparation, ointment transdermal preparation or microneedle transdermal preparation. The present invention also relates to the application of the above-mentioned medicine in the treatment of hemangioma. Using the medicine of the invention to treat infantile hemangioma can promote the efficiency of diseased cells to absorb medicine, improve the treatment effect, reduce the dosage of medicine, and have no adverse reaction in the treatment process.
Owner:BEIJING MERSON PHARMA CO LTD
Traditional Chinese medicine formula for treating infant epidermal hemangioma
InactiveCN102228529AGood effectReasonable drug compatibilityAnthropod material medical ingredientsHydroxy compound active ingredientsSide effectCuticle
The invention provides a traditional Chinese medicine formula for treating infant epidermal hemangioma, relates to the technical field of medicaments. The formula contains the following ingredients: 1-4 parts of croton, 2-8 parts of borneol, 6-15 parts of prepared radix aconiti kusnezoffii, 6-15 parts of Ligusticum chuanxiong, 10-20 parts of unprocessed rheum officinale, 10-20 parts of dutchmanspipe root, 10-20 parts of Eupolyphaga sinensis, 10-20 parts of safflower and 25-35 parts of Clematis chinensis. The traditional Chinese medicine formula for treating infant epidermal hemangioma provided by the invention has the beneficial effects that: the medicine compatibility is reasonable; the combined use of croton, borneol, unprocessed rheum officinale, Eupolyphaga sinensis and safflower has the functions of detumescence, blood breaking, stasis eliminating, diuresis and obstruction removing; and prepared radix aconiti kusnezoffii, Ligusticum chuanxiong, Aristolochia contorta and Clematis chinensis have the functions of decay removing, stasis removing and qi circulation promoting. Due to the combined use of the medicinal materials, the traditional Chinese medicine formula has good treatment effect on infant congenital epidermal hemangioma, strawberry hemangioma and simple hemangioma, and has the characteristics of no pain, no toxic or side effects, no scar leaving, etc.
Owner:张佑强
Chinese medicinal composition for treating superficial tumor
InactiveCN101708299ASignificant effectHeavy metal active ingredientsMammal material medical ingredientsMyrrhFacial region
The invention discloses a Chinese medicinal composition for treating a superficial tumor, which comprises the following components by mass: 10 to 30 grams of java brucea fruit; 10 to 30 grams of walnut kernel; 8 to 15 grams of unprocessed rhizoma pinelliae; 8 to 15 grams of common burreed rhizome; 3 to 8 grams of calomel; 3 to 8 grams of frankincense; 3 to 8 grams of myrrh; and 1 to 2 grams of polythrinicium. The medicinal composition is prepared by grinding the raw material medicaments respectively, uniformly mixing the powders and putting the powder into bottles. When the Chinese medicinal composition is used, the raw material medicaments are prepared into a paste by adding the right amount of white vinegar; and the paste is externally applied to affected parts of the tumor to block blood supply around the tumor to make the tumor die naturally. Clinical application shows that the Chinese medicinal composition has obvious curative effect on hemangioma, thyroidtumor and neurofibroma; a few scars are left after healing, but can be faded out gradually in the future; and the facial region is recovered well.
Owner:谢足仔
Intermittent air-compression treatment device for hemangioma
ActiveCN109730741AFirmly connectedGuaranteed compression effectTourniquetsAgainst vector-borne diseasesAir compressionEngineering
The invention discloses an intermittent air-compression treatment device for a hemangioma. The intermittent air-compression treatment device comprises a bandage, a support, a motor, a rotary shaft, discs, a receding groove, a connecting plate, a sliding pin, an oval pillar, a compression plate, a connecting pin, a fixing plate, an air bag, springs and an air cushion. The intermittent air-compression treatment device is ingenious in structure, powerful in function and easy to operate; through the device, the hemangioma of a child patient is in an intermittent air compression state to be subjected to compression treatment, and the compression effect of the child patient with hemangioma is ensured.
Owner:王崇宝
Traditional Chinese medicine preparation for cutaneous hemangioma and preparation method thereof
InactiveCN104984265AWith promoting blood circulation and regulating menstruationGood pain reliefPill deliveryAntineoplastic agentsMyrrhSide effect
Owner:宋艳霞
Application of levo-propranolol in preparing medicament for treating vasculopathy
PendingCN110314154AGood treatment effectOrganic active ingredientsAntineoplastic agentsDexpropranololTherapeutic effect
The invention provides application of levo-propranolol in preparing a medicament for treating vasculopathy. During treatment of vasculopathy, particularly treatment of hemangioma, the treatment effectof the levo-propranolol is better than those of racemic propranolol and dextro-propranolol, and a good prospect is provided for the clinical treatment of hemangioma or infantile hemangioma.
Owner:武汉恒信源药业有限公司
Application of embellin in preparation of medicament for inhibiting angiogenesis
InactiveCN101278925AEnhanced inhibitory effectOrganic active ingredientsSenses disorderDiseaseEmbryo
The invention relates to a novel use of Chinese herbal medicine monomer embelin, in particular to an application of the embelin in a preparation of a drug for inhibiting angiogenesis. The embelin is applied in the inhibition of angiogenesis dependent disease such as mammary cancer, colon cancer, lymphoma, acute myelocytic leukemia, rheumatoidarthritis, psoriasis, diabetic syndrome, hemangioma, etc. Experiments show that the embelin has remarkable inhibitory action in proliferation experiment, migration experiment, invasion experiment, cell tabulation experiment, the angiogenesis of chick embryo allantois, etc. in the human microvascular endothelial cells (HMEC-1), thereby being used for preparing the drug for inhibiting the angiogenesis.
Owner:EAST CHINA NORMAL UNIVERSITY
Hemangioma laser therapeutic head
InactiveCN1775181ASolve application problemsLow cost of treatmentSurgical instrument detailsRadiation therapyNoseLight beam
The present invention relates to a laser therapeutic head for curing angioma. It includes a shell body, and is characterized by that in the shell body is fixedly mounted a lens capable of making laser beam focused focal distance be 6-9cm, one end of the shell body is connected with laser outlet end of laser generation device, on another end of said shell body a telescopical knife nose is mounted, and on the laser beam outlet end of said telescopical knife nose is set a positioning bar which is conveniently observed by operator, and the length of the telescopical knife nose must make the diameter of laser facula formed in the top end of said positioning bar be 3-7mm.
Owner:王之光 +1
Human angioma rat animal model and its configuration method
The present invention transplants hemangioma endothelial cell and tumor cell or tumor cell releasing product isolating cultured from human hemangioma structure, to immunologic deficiency mouse hypodermic, to obtain human hemangioma mouse animal model. The present invented technology method is portably in technical operation and with high model success ratio, the experimental evidence proving that said blood vessel endothelial cell in hemangioma model established is human hemangioma endothelial cell, and said model having the pathology property of human angiomatous intumescentia blood sinus and rebirth capillary vessel. Said hemangioma animal model can be used in system researching angiomatous pathogenesis screening human angiomatous therapeutic drug.
Owner:SUZHOU BOJUHUA BIOMEDICAL TECH CO LTD
Chinese medicine for treating cutaneous hemangioma
InactiveCN101209338ANo scarNo side effectsAnthropod material medical ingredientsHydroxy compound active ingredientsCentipedeMonkshoods
The invention discloses a traditional Chinese medicine for the treatment of skin hemangioma, which takes kusnezoff monkshood root, Chinese gall, golden thread, centipede, scorpion, common monkshood mother root, doubleteeth pubescent angilica root, divaricate saposhnikovia root, ophicslcite, solanum dulcamara linn, dahurian angelica root, oyster shell, zedoary, peach seed and alocasia rhizome as the raw materials; the raw materials are smashed into medical powder, the power, borneol and glycerol are mixed by the weight mixing ratio of 1: 1: 2, and the ointment is prepared by the conventional method. The invention selects the pure natural traditional Chinese medicines as the raw materials, all the components are in line with the stipulations of pharmaceutical control law, the invention has the curing effect for skin hemangioma by making use of the comprehensive function of all the traditional Chinese medicines; furthermore, no scar is left, and the total effective rate is 100 percent.
Owner:刘学键
Method for automatically extracting and quantifying color of lesion area of infantile hemangioma
ActiveCN108921179ARealize automatic extractionAchieve quantificationImage enhancementImage analysisSupport vector machineMean vector
The invention discloses a method for automatically extracting and quantifying the color of a lesion area of an infantile hemangioma. The method comprises the steps of extracting a lesion part in an image of the infantile hemangioma, marking the lesion part as the lesion area and marking the remaining part as a skin area; converting color space of the lesion area and the skin area from red green blue (RGB) to international commission on illumination (CIE) Lab; extracting a mean value of chromatic values of three channels of the skin area to obtain a mean vector of the chromatic value of the skin area; extracting the mean value of chromatic values of three color channels of the lesion area to obtain the mean vector of the chromatic value of the lesion area; calculating distance by utilizingthe mean vector of the chromatic value of the skin area and the mean vector of the chromatic value of the lesion region, wherein the distance comprises Euclidean distance, Manhattan distance, Chebyshev distance, included angle cosine distance and related distance; and inputting the distance into an SVM (Support Vector Machine) classification model and outputting a classification result to realizeautomatic quantification of the color of the lesion area of the infantile hemangioma. Through the method disclosed by the invention, the automatic extraction and quantification of the color of the lesion area of the infantile hemangioma are realized.
Owner:UNIV OF ELECTRONICS SCI & TECH OF CHINA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com